Twist Bioscience (NASDAQ:TWST – Free Report) had its price objective decreased by Robert W. Baird from $187.00 to $135.00 in a report issued on Friday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.
TWST has been the topic of a number of other research reports. UBS Group began coverage on Twist Bioscience in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $144.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, September 21st. Jefferies Financial Group assumed coverage on shares of Twist Bioscience in a research report on Thursday, October 8th. They set a “hold” rating and a $150.00 price objective for the company. Barclays increased their price objective on shares of Twist Bioscience from $112.00 to $215.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Finally, Canaccord Genuity Group decreased their target price on shares of Twist Bioscience from $205.00 to $150.00 and set a “buy” rating on the stock in a report on Friday. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $141.00.
View Our Latest Report on Twist Bioscience
Twist Bioscience Stock Performance
Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07. The firm had revenue of $126.64 million for the quarter, compared to analyst estimates of $123.55 million. Twist Bioscience had a negative return on equity of 27.53% and a negative net margin of 28.34%. The business’s revenue for the quarter was up 26.7% on a year-over-year basis. Analysts anticipate that Twist Bioscience will post -1.52 earnings per share for the current year.
Insider Transactions at Twist Bioscience
In related news, insider Dennis Cho sold 949 shares of the company’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $135.40, for a total transaction of $128,494.60. Following the completion of the sale, the insider directly owned 62,840 shares in the company, valued at $8,508,536. This represents a 1.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 1,007 shares of the company’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $135.40, for a total value of $136,347.80. Following the sale, the senior vice president owned 105,625 shares of the company’s stock, valued at approximately $14,301,625. This represents a 0.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 495,279 shares of company stock worth $80,489,387. 3.08% of the stock is owned by insiders.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of TWST. BlackRock Inc. acquired a new position in Twist Bioscience during the 2nd quarter worth approximately $600,191,000. William Blair Investment Management LLC acquired a new stake in Twist Bioscience in the second quarter valued at approximately $223,722,000. Bank of America Corp DE acquired a new stake in Twist Bioscience in the second quarter valued at approximately $94,922,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Twist Bioscience during the first quarter worth $22,563,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Twist Bioscience during the second quarter worth $19,722,000.
Key Headlines Impacting Twist Bioscience
Investors following TWST have been watching these headlines:
- Positive Sentiment: Fiscal Q1 2027 revenue guidance of $130 million–$132 million is above the $126.3 million consensus estimate. Article: Twist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results
- Neutral Sentiment: Fiscal 2027 revenue guidance of $550 million–$560 million is only modestly above the $549 million consensus, which may have disappointed investors looking for a stronger outlook. Article: Twist Bio slips despite Q4 beat after underwhelming FY27 outlook
- Negative Sentiment: Leerink Partners cut its price target to $175 from $190, TD Cowen to $137 from $190, and Baird to $135 from $187. Each maintained a positive rating—outperform or buy—but the reductions indicate more cautious valuation expectations. Leerink Partners ratings
Twist Bioscience Company Profile
Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.
Further Reading
- Five stocks we like better than Twist Bioscience
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
